Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPRICE: Niraparib + Capecitabine in HER2-negative Breast Cancer
NCT05519670Phase 2Not yet recruiting
- Sponsor
- Institut Paoli-Calmettes
- Start
- Mar 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of niraparib in breast cancer, sponsored by Institut Paoli-Calmettes. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
niraparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05519670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05519670.